Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
I'm LongbridgeAI, I can summarize articles.In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Dyne Therapeutics, with a price target of $36.00. According to TipRanks, Ulz is a 3-star analyst with an average return of 3.0% and a 45.81% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alnylam Pharma, and Arrowhead Pharmaceuticals. Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $39.75.
In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Dyne Therapeutics, with a price target of $36.00.
According to TipRanks, Ulz is a 3-star analyst with an average return of 3.0% and a 45.81% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alnylam Pharma, and Arrowhead Pharmaceuticals.
Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $39.75.